• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Healthabortion

Abortion pill distributor sees no surge or shortages after Roe v. Wade overturned: ‘We are very confident in our position’

By
Christine Mui
Christine Mui
Down Arrow Button Icon
By
Christine Mui
Christine Mui
Down Arrow Button Icon
June 28, 2022, 2:14 PM ET
Mifepristone (Mifeprex) and Misoprostol, the two drugs used in a medication abortion, are seen at the Women's Reproductive Clinic, which provides legal medication abortion services, in Santa Teresa, New Mexico. Mifepristone is taken first to stop the pregnancy, followed by Misoprostol to induce bleeding.
Mifepristone (Mifeprex) and Misoprostol, the two drugs used in a medication abortion, are seen at the Women's Reproductive Clinic, which provides legal medication abortion services, in Santa Teresa, New Mexico. Mifepristone is taken first to stop the pregnancy, followed by Misoprostol to induce bleeding. Robyn Beck-AFP Via Getty Images

The provider behind the abortion pill Mifeprex says it’s ready for whatever comes after the Supreme Court reversed Roe v. Wade last Friday, removing the constitutional right to abortion. 

Last week, before the ruling, Danco Laboratories predicted it would have adequate supply to handle a rush of women seeking self-managed abortions. “We are prepared for any surge,” a company spokesperson told ABC News. “Our supply is stable and plentiful.”

Now Danco, which distributes the abortion-inducing drug mifepristone under the brand name Mifeprex, said it has yet to experience shortages and maintains it can handle any post-Roe demand, reports Bloomberg.

“We are very confident in our position to be able to meet whatever surge in demand may come up especially in those states that become safe haven[s] for women in banned states,” Abby Long, a spokesperson for Danco, told Bloomberg. 

For more than 20 years, the Food and Drug Administration has approved the use of mifepristone to end a pregnancy that is less than 10 weeks along. According to the FDA, the drug works by blocking the hormone progesterone and is typically followed by another medication, misoprostol, which causes cramping and bleeding to empty the uterus. 

More than half of U.S. abortions that took place in 2020 used abortion pills, according to a report from the Guttmacher Institute, an abortion-rights research organization. 

The medication is currently not available over the counter, but Danco Laboratories told ABC it is working with federal regulators to allow pharmacies to carry the drug by the end of the year. Danco was the U.S.’s only provider of abortion pills until the FDA approved a generic version of mifepristone from GenBioPro in 2019. 

Neither Danco Laboratories nor GenBioPro responded to requests for comment from Fortune.

However, providers of telemedicine abortion care are anticipating and preparing for more demand to come. These services connect patients with medical providers for online consultations and send out abortion pills by mail, where state laws allow. 

Virtual clinic Hey Jane said that following the Supreme Court’s decision, its site traffic grew nearly 10 times, and patient demand more than doubled, compared to last month’s average. 

“This spike in interest demonstrates to us that people are increasingly curious about telemedication abortion as it becomes an exceptionally viable option in the wake of Roe’s overturn,” its CEO, Kiki Freedman, told Fortune.

The demand has come from “an increase in patients reporting that they’re coming to Hey Jane because of longer-than-expected appointment wait times” over the past few months due to restricted abortion access in states like Texas. The clinic is now treating 25 times more daily patients than 15 months ago, Freedman said. 

Another online provider of abortion pills, Just the Pill, said it received more than 260 requests following the ruling last Friday to Monday. Before, it typically received 20 to 25 requests a day. 

At the same time, pharmacies have seen a significant surge in demand for emergency contraceptives such as Plan B, causing Walmart, RiteAid, and CVS to cap the number a customer can purchase. 

“Due to increased demand, at this time we are limiting purchases of Plan B contraceptive pills to three per customer,” RiteAid told Fortune.

A spokesperson from Walmart said, “Many of our products have online purchase limits in place. During times of fluctuating demand, these limits may change.”

“Immediately following the Supreme Court decision, we saw a sharp increase in the sale of emergency contraceptives and implemented a temporary purchase limit to ensure equitable access,” CVS said. The pharmacy chain said Tuesday that sales for these products had returned to normal.

“We’re in the process of removing the purchase limits, which will take effect in-store and on CVS.com over the next 24 hours. We continue to have ample supply of emergency contraceptives to meet customer needs,” a company spokesperson told Fortune. As of Wednesday morning, the original purchase limit of three was no longer in place for both Plan B and Aftera on its website.

June 29, 2022: This story was updated to include comment from CVS.

Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Author
By Christine Mui
See full bioRight Arrow Button Icon

Latest in Health

Thompson
C-SuiteMedia
Atlantic CEO Nick Thompson on how he learned to ‘just keep moving forward’ after his famous firing at 22
By Nick LichtenbergDecember 14, 2025
3 hours ago
HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
1 day ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
1 day ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
1 day ago
Healthmeal delivery
Factor Meals Review 2025: Tester Approved
By Christina SnyderDecember 12, 2025
2 days ago
Donald Trump
HealthHealth Insurance
‘Tragedy in the making’: Top healthcare exec on why insurance will spike to subsidize a tax cut to millionaires and billionaires
By Nick LichtenbergDecember 12, 2025
2 days ago

Most Popular

placeholder alt text
Economy
Tariffs are taxes and they were used to finance the federal government until the 1913 income tax. A top economist breaks it down
By Kent JonesDecember 12, 2025
2 days ago
placeholder alt text
Success
Apple cofounder Ronald Wayne sold his 10% stake for $800 in 1976—today it’d be worth up to $400 billion
By Preston ForeDecember 12, 2025
2 days ago
placeholder alt text
Success
40% of Stanford undergrads receive disability accommodations—but it’s become a college-wide phenomenon as Gen Z try to succeed in the current climate
By Preston ForeDecember 12, 2025
2 days ago
placeholder alt text
Economy
The Fed just ‘Trump-proofed’ itself with a unanimous move to preempt a potential leadership shake-up
By Jason MaDecember 12, 2025
2 days ago
placeholder alt text
Success
Apple CEO Tim Cook out-earns the average American’s salary in just 7 hours—to put that into context, he could buy a new $439,000 home in just 2 days
By Emma BurleighDecember 12, 2025
2 days ago
placeholder alt text
Uncategorized
Transforming customer support through intelligent AI operations
By Lauren ChomiukNovember 26, 2025
18 days ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.